Tiziana Life Sciences (TLSA) News Today $0.74 -0.02 (-2.64%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$0.76 +0.02 (+2.85%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short InterestTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 680,800 shares, an increase of 300.2% from the December 15th total of 170,100 shares. Based on an average daily trading volume, of 348,300 shares, the short-interest ratio is currently 2.0 days. Approximately 1.0% of the company's shares are short sold.January 14, 2025 | marketbeat.comTiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3January 10, 2025 | markets.businessinsider.comTiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonistsJanuary 10, 2025 | proactiveinvestors.comTiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseasesJanuary 8, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological DiseaseJanuary 8, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short InterestTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 170,100 shares, a decrease of 18.3% from the November 30th total of 208,100 shares. Based on an average daily volume of 306,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.2% of the shares of the stock are sold short.December 29, 2024 | marketbeat.comSanctuary Advisors LLC Invests $864,000 in Tiziana Life Sciences Ltd (NASDAQ:TLSA)Sanctuary Advisors LLC purchased a new stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 907,613 shares of the company's stock, valued at approximately $864,000. Sanctuary ADecember 23, 2024 | marketbeat.comTiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal ForalumabDecember 17, 2024 | markets.businessinsider.comTiziana Life Sciences doses first Alzheimer's patient with intranasal foralumabDecember 17, 2024 | proactiveinvestors.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest UpdateTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 208,100 shares, a drop of 24.3% from the November 15th total of 274,900 shares. Based on an average daily volume of 261,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.3% of the shares of the stock are sold short.December 13, 2024 | marketbeat.comTiziana Life Sciences expands Phase 2 trial for non-active SPMSDecember 5, 2024 | finance.yahoo.comTiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutionsDecember 4, 2024 | proactiveinvestors.comTiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7% - Here's What HappenedTiziana Life Sciences (NASDAQ:TLSA) Shares Down 3.7% - Here's WhyDecember 4, 2024 | marketbeat.comTiziana Life Sciences secures grant for ALS trialNovember 19, 2024 | proactiveinvestors.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Up 350.5% in OctoberTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 241,900 shares, an increase of 350.5% from the October 15th total of 53,700 shares. Based on an average trading volume of 268,900 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.4% of the shares of the stock are short sold.November 12, 2024 | marketbeat.comTiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMINovember 2, 2024 | proactiveinvestors.comTiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 ConferenceNovember 1, 2024 | proactiveinvestors.comTiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study DataNovember 1, 2024 | globenewswire.comTiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapyOctober 31, 2024 | proactiveinvestors.comTiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 MillionOctober 30, 2024 | globenewswire.comTiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination StudyOctober 30, 2024 | tmcnet.comTiziana Life Sciences announces results from ozempic, nasal anti-CD3 studyOctober 30, 2024 | markets.businessinsider.comTiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesityOctober 30, 2024 | proactiveinvestors.comTiziana Life Sciences Advances with Promising Drug TrialsOctober 21, 2024 | finance.yahoo.comTiziana Life Sciences Ltd Share Chat (TLSA.US)October 18, 2024 | lse.co.ukTiziana Life Sciences awarded $4M to advance Alzheimer's disease researchSeptember 19, 2024 | proactiveinvestors.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 53.7% in AugustTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 127,100 shares, a decrease of 53.7% from the August 15th total of 274,700 shares. Based on an average trading volume of 265,800 shares, the short-interest ratio is currently 0.5 days.September 13, 2024 | marketbeat.comTiziana Life Sciences names new chief executiveAugust 19, 2024 | proactiveinvestors.comTiziana Life Sciences Appoints New Chief Executive OfficerAugust 19, 2024 | globenewswire.comTiziana Life Sciences Ltd.: Tiziana Life Sciences Granted FDA Fast Track DesignationJuly 25, 2024 | finanznachrichten.deTiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumabJuly 24, 2024 | proactiveinvestors.comTiziana Life Sciences Granted FDA Fast Track DesignationJuly 24, 2024 | globenewswire.comTiziana Life Sciences secures $3.4M in non-dilutive fundingJune 28, 2024 | proactiveinvestors.comTiziana Receives $3.4 Million in Non-Dilutive FundingJune 28, 2024 | globenewswire.comTiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapyJune 26, 2024 | proactiveinvestors.comTiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with ForalumabJune 26, 2024 | globenewswire.comTiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatmentJune 11, 2024 | proactiveinvestors.comTiziana Life Sciences reports qualitative improvement in MS patients treated with lead assetJune 6, 2024 | proactiveinvestors.comTiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trialJune 4, 2024 | proactiveinvestors.comTiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis ResearchMay 30, 2024 | globenewswire.comTiziana eyes orphan drug designation for multiple sclerosis treatmentMay 13, 2024 | proactiveinvestors.comTiziana Life Sciences Files for Orphan Drug Designation for Intranasal ForalumabMay 13, 2024 | globenewswire.comTiziana Life Sciences Ltd Ordinary Shares TLSAMay 3, 2024 | morningstar.comTiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patientsApril 25, 2024 | proactiveinvestors.comTiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabApril 25, 2024 | globenewswire.comTiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access ProgramApril 23, 2024 | proactiveinvestors.comTiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access ProgramApril 23, 2024 | globenewswire.comTiziana Life Sciences reports additional positive results from Multiple Sclerosis programApril 22, 2024 | proactiveinvestors.comTiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access ProgramApril 22, 2024 | globenewswire.comTiziana Life Sciences' foralumab study highlighted in Neurology TodayApril 19, 2024 | proactiveinvestors.com Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Media Mentions By Week TLSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSA News Sentiment▼0.470.49▲Average Medical News Sentiment TLSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSA Articles This Week▼01▲TLSA Articles Average Week Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BTMD News Today TNGX News Today ATYR News Today ITOS News Today TRVI News Today DSGN News Today AVIR News Today AQST News Today RZLT News Today IMMP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
